but the shocker is zenka has moved ahead of clovis.zenka was supposed to be six months behind. now it looks like they're three months ahead of clovis. >> is there a shot to get off of the price target here or there, that clovis does beat astrazeneca to market being though this is a breakthrough drug on both parts? >> if you look -- both drugs are really good. zenka's drugs doesn't have side effects. it causes increase in blood sugar and changes the conduction in the heart. zenka is going to file in the first quarter of next year, they have been able to enroll a lot more patients than clovis. we're talking about coming to the market second with a profile not clearly safe. there's also another drug that they have which is ovarian cancer. astrazeneca has gotten ahead of that drug, too. there is residual value here. >> so they have about $300 million i think. you probably know better than me. they probably burned $20 million or so a quarter. so at this price given this plush, i know what your price target is. i think it's 53. does this fee

clovis oncology stock taking a hit. down more than 7% on news its experimental lung cancer drug is linked to diabetes. the company's ceo will explain what's going on and if there's hope for a turnaround coming up. >> also ahead, two apple pros will give us their take on the latest announcements coming from apple's developer conference in san francisco going o.so far the company is not impressing investors today. does the street have it wrong? we'll talk about that coming up next. [ girl ] my mom, she makes underwater fans that are powered by the moon. ♪ she can print amazing things, right from her computer. [ whirring ] [ train whistle blows ] she makes trains that are friends with trees. ♪ my mom works at ge. ♪ . >>> welcome back. starting the week after stronger than expected. maybe it was stronger than expected data on manufacturing here this morning in the u.s. >> many different expectations. >> looks like stocks are trying to find their direction. dow adding 20 point and the s&p is barely higher and the nasdaq nega

sam clovis is running against ernst and he joins me now on the phone.ill joni ernst get to 35% of the vote or not tonight. is that the right question we should be asking? >> i think you ought to be talking to her about that. i'm not interested in that particular point. i think we have a very crowded field. i think that if you take a look at the poll, and i think you need to take a look at the cross tabs and i think you'll find that the support is very soft. there's no definitive real leader. i think it's as much as name recognition as it is commitment to a candidate. so i think there's going to be a lot of dynamics in play today. we've got weather systems moving through that will have an effect. we've had a lot of other factors to look at, so i think we're a long ways from determining who the next senator from iowa is going to be. >> and quickly, mr. clovis, i wanted to ask you if joni ernst is the nominee, would you endorse her? would you be comfortable with her as the republican nominee, comfortable with her as a republican nominee? >> well, in the st

shares of clovis oncology getting slammed. yesterday, clovis said 22% of patients in its early stage study testing its experimental lung cancer drug experienced high blood sugar levels. dollar general, the biggest winner in the s&p 500 today. the discount retailer missing earnings estimates blaming tough competition and the harsh winter weather put said sales did rise and its expansion plan is still on track. >>> euro currency, over the past month or so. the reason that's important is there is a huge short on the currency now. the betting is it will weaken going into the european central bank meeting on thursday. mario draggo hopes it will too. but that may be the opposite of what happens. sarah eisen is here on how you might want to play it. >> this has grown this bet against the euro. $2.8 billion short bet right now. double what it was the previous week. but that may back fire. thursday, the most anticipated european central bank decision of the year. traders are expecting an array of policy moves like cutting interest rate

another tough day for clovis oncology shares.is said 22% of patients in an early stage study testing its lung cancer drug experienced high blood sugar levels following a 7% drop from yesterday. stock down another 15% near session lows today. carl, another rough day for clovis. back over to you guys. >> thanks so much. the nhl's long awaited stanley cup finals one day away. represents a rare sport duel between two of the top tv markets as the rangers take on the kings for the cup froe trophy. joining us is gary betman jones us live from 30 rock. good morning. >> good morning. great to be with you. fun time of year. >> i want to talk about ticket sales but sports league of the year, sports event of the year in the winter classic, sports executive of the year, yours truly. what's going on in hockey? >> we're in a very good place. we've spent a fair amount of time trying to build a foundation for our game, making sure the game on the ice is healthy, entertaining, exciting and competitive and at the same time building our businesses a

i'm long clovis. this is up 102% year-to-date. clovis is down 24%. shame i own the wrong one. i'm not buying it here. >> a drop for -- >> it's a deal that still continues to haunt the company. you're wondering whether they're ever going to pay a dividend. it was part of why you owned this stock. shareholder fighting. it's no touch right now even though there's a lot of value. >> a pop for trulia. >> they had a lot of activity on their site that looked like home buying might be picking up. the home builders themselves did not move as much as i thought they would. i think that sector is still trouble. >> a pop for alcoa. >> analyst upgrade. another one earlier in the month. timmy talked about this for a while. we talked about this a couple quarters ago. it's rallying off a quarter. it scares me when analysts start to get on board. not a bad place 14.5 but i think there's more upside in the name. >> and we have a drop for pit bull's pants. >> last year they took center stage at the world cup opening ceremonies but it was his rapper's pants that stole the show. mankles and mom's c

. >> clovis oncology up 6%. >> they released the stocks but hammered today. you get an upgrade.at's positive. buff they have got to perform. i think this is one of those dead cap balances. >> we have got a drop for guesswork. it was a wheel of fortune contestant who tried to solve the puzzle. listen. >> where do we go. >> no. >> couldn't even read. >> of course, surf city here we come is a lyric from the surf city. surf, here we go is an epic fail. i mean, the last four lateetter- >> i'm sure none of his friends saw. making no comment whatsoever. >> shares of apple up about 23% since reporting earnings. announcing it will be gin trading at the new price monday. we have seen unusual activity. >> massive call buying. yesterday somebody bought $58 million of premium in calls. the 675 strike and the 700 strike. obviously that's going to be split 7 for 1 monday. but that's implying to break even on the 675 that gets you back to the september 2012 highs here. i never thought it would have happened. i'm the wrong guy to ask. i think the company is just fine. i thought wwc was fine. i t

. >> now, on the flip side, clovis oncology was down about 7%.tors were concerned about some side effects which caused high blood sugar in some patients and some concern about the severity of the side effect which he add rressed with us. >> we had three patients that did go on insulin but no we do not cause diabetes. >> saying we do not cause diabetes is the word from them today. we could be seeing more stock movers tomorrow. >> thanks for that. meg joining us from chicago. pete, you have got a lot of trades mostly in the big cap. >> right. and talking to the guys who know everything about these different companies said keep an eye on the big pharma names. i think they're right. when you look at the headline stories it's bristol meyers. astrazeneca, big cap pharma names. but you want to look at the biotech names because that will be the pipelines at some point in the future. this is the area now where the big pharma names are looking forward and saying this is somebody we have got to grab up for our pipeline to increase. >> what did you buy into

in an exclusive interview with clovis ceo, mat trick mahaffy will be on. after positive result os of a study of its leukemia cancer patients, they're up 9% on that bit of news. back to you guys. >> thanks so much. there's the stock moving and let's hear from the man behind the company. pharmacist chairman ceo, dr. harvey. >> thanks so much. i'm here with dr. harvey. thanks for joining us. >> thanks. >> your drug was pulled for a little while over safety concerns and approved to re-enter in december and obviously people are happy about it. what do you think investors are responding to? >> i think they're responding to the overall picture. very strong efficacy data both in leukemias, new solid tumor indication called gist, and a better understanding of the safety profile. physicians know, i think, how to use the drug a lot better today than perhaps as recently as three or six months ago. >> there has been some question since the drug was pulled about can it be used as a first option for patients. you reported some data on it being used in a lower dose and ma

stock number four, interesting call, clovis oncology, downgrade. >> i don't like putting the calls in tell you why we didn't in a second. that's a tease. they had early stage results of a lung cancer treatment, disappointed wall street. now citigroup is out and, get this, here is the news of the th. they slashed their target to 53 from 109. >> look where it is. >> yeah. the target is still above where it is. that's why i hate this kind of call. but you see a target price cut by basically 50%, not quite, it is noteworthy, i think. >> it is. under the radar name of the day, interdigital, wireless research development company. the ticker is idcc. if you have not heard of him before. >> the company is upgrading itself today, earlier they entered a patent license deal with samsung ending all pending litigation between the two companies. also announcing they have updated the revenue outlook. up 18%, nearly 7 bucks a share. we'll end on happy news here. >>> from strategy talk to eet t check. herb greenberg with reality check. when you're in town from the west coast and mansion on the beach,

southeast of san jose two tornadoes touched down in the town of clovis.ed or no one was hurt. we have extreme weather to talk about with an update on both national and local forecast with any. >>: the extreme heat in just a minute we get basically that storms coming through the flames and nebraska. this is producing potential severe thunderstorms for these locations dropping a lot of weight range. rain , anoy without hundred + were looking at the sea breeze coming back but it won't be as warm. the cooling continues for the rest of the week. oakland 65 san jose 69 already livermore and the lower 76 some were warming up pretty quickly out there. 97 clara 87 apollo also. fairfield is hitting one no one antioch and livermore heeding 195 and danville.100 articles they looks to be thursday it will be drive for the next seven days. >>: walnut creek road and have, terisa estacio talking about what's going on there. >>: or john the people on this early monday morning on how they plan to beat the heat. >>: so what's your strategy to beat the heat today? >>: i actua

it seems that in a race with clovis oncology, whose drug in 1686 and astrazeneca's drug azd-9291, theseve. the data at asco is showing that maybe astrazeneca is winning out on the tolerability of things. >> joseph, early days but interesting announcements. thanks for joining us. analyst at data monitor health care. >>> still to come, bill gross's money problems, why investors continue to pull cash from people kos-- pimco's bond funds even as performance is starting to improve. >>> you're watching "worldwide exchange." >>> a recap of the headlines. obama lands in europe where he'll met the new president of ukraine. >>> france calls bnp's potential $10 billion fine unreasonable. >>> and pimco feels the pinch as they see the 13th month of outflows. >>> our apologies for that. pimco, money flows in, money flows out. new data from morningstar shows the world's biggest bond fund continues to see cash heading out the door. bertha coombs is at cnbc in the states with more details on this, bertha. sometimes you think performance helps but in this case it doesn't. >> no. well, no. the marve mans

casinos falling after ma could you gaming revenue said was up better than a weaker 9% in may and clovisng hit for the second consecutive trading session following news that its lung cancer drug cost patients in an early stage trial to experience higher blood sugar levels. the ceo was on cnbc yesterday defending the drug. >> we had three patients who were when this first emerged we didn't know how to treat it and had to go on insulin briefly but no, it does not cause diabetes. >> at&t is falling despite raising its full-year revenue guidance due to strong trends in its wireless business, down 3/4 of a percent. even in today's trade. back over to you. >> thanks very much, dom. does this put at&t into the conversation for investors when investing in telecom, or is verizon the one to own now? >> let's ask our guests. great to see you both, look, we saw a lot of hedge funds piling into verizon in the latest batch of filings, michael, but is it time to take a fresh look at at&t? >> we actually like both stocks. i think at&t has caught a bit of a black eye because of the quote, unquote, immuni

there's competing data from clovis oncology.treat cancer, the biggest killer of cancer throughout the world. >> there are certain types of patients with lung cancer. 25% have a specific abnormality in their cancer that there are medicines for today. they become resistant. once they become resistant, then there aren't any other medicines for them. this has efficacy and seems to be well tolerated. patients who have advanced cancer, there's a potential they will have a good benefit without a lot of side effects. >> thank you so much for joining us. >> my pleasure. >> andrew, back to you guys. >>> coming up, stocks to watch when the opening bell rings on wall street. income in equality and the book that has everybody buzzing. thomas piketty author of "capital in the 21st century". before we go, dow the opening up close to 12 points higher. she's still the one for you. and cialis for daily use helps you be ready anytime the moment is right. cialis is also the only daily ed tablet approved to treat symptoms of bph, like needing to go